Ani Pharmaceuticals (ANIP) Net Cash Flow (2010 - 2026)

Ani Pharmaceuticals (ANIP) has 17 years of Net Cash Flow data on file, last reported at $25.4 million in Q1 2026.

• For the quarter ending Q1 2026, Net Cash Flow rose 385.49% year-over-year to $25.4 million; the trailing twelve-month figure through Mar 2026 stood at $161.2 million (up 306.63% YoY), and the FY2025 full-year result was $141.0 million, up 286.07% from the prior year.
• Net Cash Flow grew to $25.4 million in Q1 2026, from $24.3 million in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $94.0 million in Q2 2023 to a low of -$95.0 million in Q3 2024.
• A 5-year average of $12.1 million and a median of $11.5 million in 2024 frame the typical range for Net Cash Flow.
• Across the five-year window, Net Cash Flow slumped 1567.69% in 2022 and soared 8844.12% in 2025, its largest moves.
• Tracing ANIP's Net Cash Flow over 5 years: stood at -$8.0 million in 2022, then jumped by 448.36% to $28.0 million in 2023, then sank by 99.03% to $272000.0 in 2024, then soared by 8844.12% to $24.3 million in 2025, then rose by 4.55% to $25.4 million in 2026.
• Business Quant data shows ANIP's Net Cash Flow at $25.4 million in Q1 2026, $24.3 million in Q4 2025, and $44.2 million in Q3 2025.